南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

CRISPR纳米系统靶向DNA错配修复通路增强免疫检查点阻断癌症免疫治疗

Targeting DNA mismatch repair pathway by CRISPR nanosystem for boosting checkpoint blockade cancer immunotherapy

Xue Dong, Pei Pan, Qiu-Ling Zhang, Jing-Jie Ye, Peng Bao, Xuan Zeng, Xian-Zheng Zhang

Journal:Nano Today

IF:18.96

DOI:10.1016/j.nantod.2022.101555

PMID:

Published:2022-07-13

research field:功能基因组学媒介生物学分子生物学基因编辑遗传学昆虫学

Abstract

Immune checkpoint blockade (ICB) therapy has exhibited great clinical benefits in multiple cancers types. However, most cancer patients such as colorectal cancers (CRC) show poor response to ICB. Here, we develop a magnetic nanoparticle (MNP)-mediated delivery of CRISPR/Cas9 system (LMPM) to target the DNA repair pathway and inactivate endogenous DNA mismatch repair (MMR)-related Mlh1 gene as a new strategy of immunotherapy. The genetically knockout of Mlh1 can be effectively realized by CRISPR/Cas9 edition with external magnetic field control. As a consequence, the inactivation of Mlh1 lead to an increased tumor mutation burden and enhancement of tumor immunogenicity in situ , which can elicit strong antitumor immunity. Both in vitro and in vivo studies demonstrate that deploying such a strategy of targeting inactivation of Mlh1 shows high inhibition efficacy in the established tumors. In this way, tumor infiltration of CD8 + T cells and ICB response are significantly improved compared with α-PD1 monotherapy. In short, it is certified that precision targeting of DNA MMR pathway can boost specific anti-tumor immune response and display the potent potential in versatile tumor immunotherapy therapeutic exploitation.

本文使用的Yeasen产品

购物车
客服
转染试用